$4.20
+5.3%Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.
Strong working capital position provides significant operational flexibility and financial cushion.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.
IRD • NASDAQ
| Opus Genetics, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
45.1M | 30.3M | 50.5M | 42.6M | 24.5M | 16.4M | 1.5M | |
0.0 | 2K | 15K | 49K | 219K | 0.0 | 0.0 | |
45.1M | 30.3M | 50.5M | 42.7M | 24.8M | 16.4M | 1.5M | |
3.2M | 5.8M | 2.3M | 4.9M | 0.0 | 0.0 | 125K | |
3.2M | 3.6M | 926K | 1.3M | 0.0 | 0.0 | 0.0 | |
0.0 | 2.2M | 1.4M | 3.6M | 0.0 | 0.0 | 125K | |
0.0 | 0.0 | 997K | 1.4M | 1.2M | 1.2M | 19K | |
1.8M | 515K | 102K | 80K | 71K | 26K | 81K | |
50M | 36.6M | 53.9M | 49M | 26.1M | 17.7M | 1.8M | |
NON-CURRENT ASSETS | |||||||
199K | 252K | 0.0 | 6K | 10K | 14K | 22K | |
199K | 252K | 0.0 | 6K | 10K | 14K | 22K | |
50.2M | 36.9M | 53.9M | 49M | 26.1M | 17.7M | 1.8M | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
3.3M | 3.1M | 2.2M | 1.4M | 1.6M | 1.2M | 342K | |
3.3M | 3.1M | 2.2M | 1.1M | 1.6M | 1.2M | 342K | |
0.0 | 0.0 | 0.0 | 315K | 0.0 | 0.0 | 0.0 | |
0.0 | 8.1M | 1.8M | 1.4M | 1.7M | 2M | 621K | |
0.0 | 0.0 | 0.0 | 0.0 | 538K | 0.0 | 5.7M | |
0.0 | 0.0 | 0.0 | 315K | 0.0 | 0.0 | 0.0 | |
4.5M | 2K | 74K | 0.0 | 0.0 | 0.0 | 2.7M | |
7.8M | 11.3M | 4M | 2.8M | 3.9M | 3.2M | 9.3M | |
NON-CURRENT LIABILITIES | |||||||
27.1M | 18.8M | 0.0 | 0.0 | 0.0 | 28M | 0.0 | |
27.1M | 18.8M | 0.0 | 0.0 | 0.0 | 28M | 0.0 | |
34.9M | 30.1M | 4M | 2.8M | 3.9M | 31.1M | 9.3M | |
SHAREHOLDERS' EQUITY | |||||||
7K | 3K | 2K | 2K | 2K | 1K | 0.0 | |
203.9M | 145.7M | 131.4M | 117.7M | 111.6M | 19.2M | 495K | |
-188.6M | -139M | -81.5M | -71.5M | -89.4M | -32.7M | -8.1M | |
15.3M | 6.7M | 49.9M | 46.2M | 22.2M | -13.5M | -7.6M | |
15.3M | 6.7M | 49.9M | 46.2M | 22.2M | -13.5M | -7.6M | |
SUMMARY | |||||||
50.2M | 36.9M | 53.9M | 49M | 26.1M | 17.7M | 1.8M | |
0.0 | 2K | 15K | 49K | 219K | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 538K | 0.0 | 5.7M | |
-45.1M | -30.3M | -50.5M | -42.6M | -24M | -16.4M | 4.1M | |
59,908,055 | 59,908,055 | 59,908,055 | 59,908,055 | 59,908,055 | 59,908,055 | 59,908,055 |
IRD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 24, 2026 | April 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 22, 2026 | April 20, 2026 | 2026 | |
S-3/A S-3/A (Amended) N/A | April 21, 2026 | April 21, 2026 | ||
8-K 8-K 2026 N/A | April 07, 2026 | April 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 07, 2026 | April 02, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 23, 2026 | April 20, 2026 | 2026 | |
S-3 S-3 N/A | March 13, 2026 | March 13, 2026 | ||
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 |
Continue your IRD research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.